Syndrome of rapid-onset end-stage renal disease: A new unrecognized pattern of CKD progression to ESRD

Renal Failure

Volumn 32, Issue 8, 2010, Pages 954-958

  Onuigbo, MacAulay A C ^a,b,c  

^a MAYO CLINIC   (United States)

^b Mayo Health System Practice Based Research Network MHS PBRN   (United States)

^c Mayo Health System   (United States)

Author keywords

Acute kidney injury; Arterio venous fistula; Chronic kidney disease; End stage renal disease; Reno protection; Syndrome of rapid onset ESRD

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL PROTECTION; SYNDROME OF RAPID ONSET END STAGE RENAL DISEASE;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SYNDROME; TIME FACTORS;

EID: 77955950287     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.502608     Document Type: Article

References (31)

1. Canadian Institute for Health Information, Treatment of End-Stage Organ Failure in Canada, 1999 to 2008-CORR 2010 Annual Report. Ottawa, ON: CIHI; 2010.
2. Stewart JH, McCredie MR, Williams SM, Jager KJ, Trpeski L, McDonald SP, ESRD Incidence Study Group. Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrology (Carlton). 2007;12(5):520-527.
3. Imai E, Horio M, Iseki K, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11(2):156-163. Epub 2007 Jun 28.
4. Chiu YL, Chien KL, Lin SL, Chen YM, Tsai TJ, Wu KD. Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan. Nephron Clin Pract. 2008;109(3):c109-c118. Epub 2008 Jul 25.
5. Afifi A, El Setouhy M, El Sharkawy M, et al. Diabetic nephropathy as a cause of end-stage renal disease in Egypt: A six-year study. East Mediterr Health J. 2004;10(4-5):620-626.
6. Collins AJ, Foley RN, Herzog C, et al. United States renal data system 2008 annual data report. Am J Kidney Dis. 2009;53(1 Suppl.):S1-S374.
7. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med. 2004;141(2):95-101.
8. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause? Kidney Int. 2005;67(5):1684-1691.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-1462. Erratum in: N Engl J Med. 1993;330(2):152.
10. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99(5):497-504.
11. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359-364.
12. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.
13. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200): 253-259. Erratum in: Lancet. 2000;356(9232):860.
14. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
15. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
16. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
17. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007;18(10): 2758-2765. Epub 2007 Sep 12.
18. Yoshida T, Takei T, Shirota S, et al. Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population. Intern Med. 2008;47(21):1859-1864. Epub 2008 Nov 4.
19. Conway B, Webster A, Ramsay G, et al. Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease. Nephrol Dial Transplant. 2009;24(6): 1930-1937. Epub 2009 Jan 30.
20. Onuigbo MA. The natural history of chronic kidney disease revisited-a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: A call for circumspection. Adv Perit Dial. 2009;25:85-88.
21. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659-663.
22. Menon V, Wang X, Sarnak MJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int. 2008;73(11): 1310-1315. Epub 2008 Mar 12.
23. Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis. 1992;20(6):533-547.
24. Onuigbo M, Onuigbo N. Chronic kidney disease progression to ESRD: Smooth and progressive versus uneven and staccato patterns-A Mayo Clinic PBRN-based patient-level data 82-month analysis of 100 high-risk CKD patients: Implications for a potential paradigm shift in current concepts of reno-protection. (Abstract presented at the May 2010 American Society of Hypertension (ASH) 25th Annual Scientific Meeting and Exposition, May 1-4, 2010). Am J Kidney Dis 2010 (abstract, in print).
25. Onuigbo MA, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): A prospective thirty-month Mayo Health System clinic experience. Med Sci Monit. 2005;11(10):CR462-CR469. Epub 2005 Sep 26.
26. Onuigbo MA, Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol. 2008;40(1):233-239. Epub 2008 Jan 15.
27. Onuigbo MA, Onuigbo NT. Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors. Ren Fail. 2008;30(1):73-80.
28. Onuigbo MA, Onuigbo NT. Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: An extended Mayo Clinic prospective 63-month experience. Ren Fail. 2008;30(4):363-371.
29. Bansal N, Hsu CY. Long-term outcomes of patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4(10): 532-533. Epub 2008 Aug 12.
30. Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20(1):223-228. Epub 2008 Nov 19.
31. Hsu CY, Chertow GM, McCulloch CE, Fan D, Ordoñez JD, Go AS. Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol. 2009;4(5): 891-898. Epub 2009 Apr 30.